AU2013201937B8 - Romidepsin formulations and uses thereof - Google Patents

Romidepsin formulations and uses thereof Download PDF

Info

Publication number
AU2013201937B8
AU2013201937B8 AU2013201937A AU2013201937A AU2013201937B8 AU 2013201937 B8 AU2013201937 B8 AU 2013201937B8 AU 2013201937 A AU2013201937 A AU 2013201937A AU 2013201937 A AU2013201937 A AU 2013201937A AU 2013201937 B8 AU2013201937 B8 AU 2013201937B8
Authority
AU
Australia
Prior art keywords
romidepsin
administered
formulation
certain embodiments
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013201937A
Other languages
English (en)
Other versions
AU2013201937A1 (en
AU2013201937B2 (en
AU2013201937A8 (en
Inventor
Willard R. Foss
Lianfeng Huang Iii
Ho-Wah Hui
Mei Lai
Vijay Naringrekar
Victor Peykov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2013201937A1 publication Critical patent/AU2013201937A1/en
Publication of AU2013201937B2 publication Critical patent/AU2013201937B2/en
Application granted granted Critical
Publication of AU2013201937B8 publication Critical patent/AU2013201937B8/en
Publication of AU2013201937A8 publication Critical patent/AU2013201937A8/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013201937A 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof Ceased AU2013201937B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586066P 2012-01-12 2012-01-12
US61/586,066 2012-01-12
PCT/US2013/021212 WO2013106696A1 (en) 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof

Publications (4)

Publication Number Publication Date
AU2013201937A1 AU2013201937A1 (en) 2013-08-01
AU2013201937B2 AU2013201937B2 (en) 2015-07-30
AU2013201937B8 true AU2013201937B8 (en) 2015-08-20
AU2013201937A8 AU2013201937A8 (en) 2015-08-20

Family

ID=47604232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013201937A Ceased AU2013201937B8 (en) 2012-01-12 2013-01-11 Romidepsin formulations and uses thereof

Country Status (8)

Country Link
US (3) US20130184225A1 (https=)
EP (1) EP2802340B1 (https=)
JP (1) JP6170946B2 (https=)
CN (1) CN104168908A (https=)
AU (1) AU2013201937B8 (https=)
CA (1) CA2863291A1 (https=)
MX (1) MX2014008390A (https=)
WO (1) WO2013106696A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630311A (en) * 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106137980B (zh) * 2015-03-31 2021-04-13 深圳翰宇药业股份有限公司 一种罗米地辛脂微球制剂及其制备方法
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
EP3773488A4 (en) * 2018-04-05 2021-11-17 Tarveda Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AT REDUCED TERT-BUTANOL LEVELS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
EP1582204B1 (en) * 1999-03-03 2013-09-25 Eli Lilly & Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
WO2002020817A1 (en) 2000-09-01 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
SI2238982T1 (sl) * 2003-06-27 2013-01-31 Astellas Pharma Inc. Terapevtsko sredstvo za mehkotkivni sarkom
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
JP2009539862A (ja) * 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
WO2008127659A2 (en) * 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
JP2010105965A (ja) * 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
RU2607526C2 (ru) * 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof

Also Published As

Publication number Publication date
US20150051157A1 (en) 2015-02-19
MX2014008390A (es) 2014-09-22
AU2013201937A1 (en) 2013-08-01
EP2802340B1 (en) 2020-10-28
CA2863291A1 (en) 2013-07-18
EP2802340A1 (en) 2014-11-19
CN104168908A (zh) 2014-11-26
AU2013201937B2 (en) 2015-07-30
US20130184225A1 (en) 2013-07-18
JP6170946B2 (ja) 2017-07-26
JP2015503623A (ja) 2015-02-02
AU2013201937A8 (en) 2015-08-20
US20160367625A1 (en) 2016-12-22
WO2013106696A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
US9980957B2 (en) Histone deacetylase (HDAC) inhibitors for the treatment of cancer
US20160367625A1 (en) Romidepsin formulations and uses thereof
ES2773315T3 (es) Formulación de AC220 secada por pulverización
ES2436266T3 (es) Métodos para administrar N-(5-terc-butil-isoxazol-3-il)-N'-{4-[7-(2-morfolin-4-il-etoxi)imidazo[2,1-b][1,3]benzotiazol-2-il]fenil}urea para tratar enfermedades proliferativas
US9795650B2 (en) Romidepsin formulations and uses thereof
TW202227090A (zh) 四環喹諾酮類似物及其鹽類的藥物組合物
CN101926780B (zh) 稳定的蒽环类化合物的冻干制剂
CN119233821A (zh) Pi3k抑制剂与pd-1抑制剂的组合疗法
AU2013205999A1 (en) Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 27 , NO 29 , PAGE(S) 4308 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME CELGENE CORPORATION, APPLICATION NO. 2013201937, UNDER INID (72) CORRECT THE CO-INVENTOR TO LAI, MEI

Free format text: IN VOL 27 , NO 29 , PAGE(S) 4328 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME CELGENE CORPORATION, APPLICATION NO. 2013201937, UNDER INID (72) CORRECT THE CO-INVENTOR TO LAI, MEI

Free format text: IN VOL 29 , NO 29 , PAGE(S) 4413 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME CELGENE CORPORATION, APPLICATION NO. 2013201937, UNDER INID (72) CORRECT THE CO-INVENTOR TO LAI, MEI

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired